ArticleFrontiers in bioengineering and biotechnology2025
Isowighteone attenuates vascular calcification by targeting HSP90AA1-mediated PI3K-Akt pathway and suppressing osteogenic gene expression.
Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Isowighteone, an isoflavonoid compound derived from Object: We investigated the efficacy of isowighteone in the treatment of vascular calcification, explored its potential mechanism, and determined whether isowighteone is a safe and effective treatment. Methods: In this study, we isolated three natural compounds and evaluated their efficacy using Results: Alizarin red staining and Calcium quantification experiments demonstrated that Isowighteone reduces aortic vascular calcification in mice and decreases calcification levels in Human aortic smooth muscle cells (HASMCs). Network pharmacology and molecular docking analysis reveals the HSP90AA1 protein as the specific target of isowighteone in HASMCs which PI3K-Akt is pivotal regulatory signaling pathway in this mechanism. Additionally, this study proved Isowighteone downregulated osteogenic gene expression in HASMCs, thereby inhibiting cellular calcification and preventing the process of VC by Conclusion: Isowighteone demonstrates significant therapeutic potential by effectively downregulating the expression of osteogenic genes, alleviating vascular calcification, and suppressing the HSP90AA1/PI3K/Akt signaling pathway, thereby improving pathological conditions associated with vascular calcification. These above results not only elucidate isowighteone as a novel therapeutic agent against VC through selective suppression of osteogenic differentiation but also position this phytochemical as a clinically candidate for VC management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.